“`html
- Zydus Lifesciences’ share has given multibagger returns to investors, with a 115 per cent jump in the last one year and a 335 per cent gain in the last five years.
- The company’s share price reached an all-time high of ₹1,172.50 on the NSE, driven by strong quarterly performance and positive growth guidance.
- “The robust Q4 performance and strong growth outlook have led analysts to revise their earnings estimates upwards,” noted a financial expert.
Explore how Zydus Lifesciences’ recent performance and future outlook are shaping its financial trajectory and investor sentiment.
Strong US growth, supported by other markets, lifted Q4 show
Zydus Lifesciences reported a revenue of ₹5,534 crore in Q4, marking a 10.4 per cent increase year over year, with significant contributions from its US operations. The company’s EBITDA grew by 23.7 per cent year over year to ₹1,630 crore, and net profit surged to ₹1,182 crore from ₹297 crore in the previous year.
Analysts up their estimates
Following the impressive Q4 results, analysts at Motilal Oswal Financial Services have increased their earnings forecasts for FY25 and FY26 by 12 per cent and 14 per cent, respectively. This adjustment accounts for Zydus Lifesciences’ niche product launches and growing market share in chronic therapies within the domestic formulation segment.
Conclusion
Zydus Lifesciences has demonstrated a robust financial performance in Q4, supported by strong growth in the US and other key markets. With analysts revising their future earnings estimates upwards, the company appears well-positioned for sustained growth, making it a potentially attractive option for investors looking at the healthcare sector.
“`
